Evaluation of Patient Satisfaction, Back Pain, and Bone Mineral Densitometry T-Scores in Patients with Postmenopausal Osteoporosis Who Received Denosumab Treatment

Evaluation of Patient Satisfaction, Back Pain, and Bone Mineral Densitometry T-Scores in Patients with Postmenopausal Osteoporosis Who Received Denosumab Treatment

Objective:This study aimed to determine the effects of denosumab therapy on bone mineral densitometry (BMD) T-scores, back pain, and satisfaction in patients with postmenopausal osteoporosis.Materials and Methods:This study included 134 patients diagnosed with postmenopausal osteoporosis and regular...

Full description

Bibliographic Details
Main Authors:	Gonca Sağlam, Dilek Çetinkaya Alişar
Format:	Article
Language:	English
Published:	Galenos Yayinevi 2021-12-01
Series:	Türk Osteoporoz Dergisi
Subjects:	denosumab bone mineral density osteoporosis back pain
Online Access:	http://www.turkosteoporozdergisi.org/archives/archive-detail/article-preview/evaluation-of-patient-satisfaction-back-pain-and-b/50628

Similar Items

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
by: Radosław Słopień, et al.
Published: (2017-10-01)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
by: Yi Chen, et al.
Published: (2021-04-01)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
by: Takako Suzuki, et al.
Published: (2017-06-01)

Osteoporosis in men: epidemiology and treatment with denosumab
by: Sidlauskas KM, et al.
Published: (2014-04-01)

Denosumab treatment in patients with different courses of osteoporosis
by: Liudmila Ya. Rozhinskaya, et al.
Published: (2017-12-01)

Denosumab for the treatment of HIV-associated osteoporosis with fractures in a premenopausal woman
by: E. Marasco, et al.
Published: (2021-04-01)

Correction: Efficacy of Denosumab in the Treatment of Postmenopausal Osteoporosis: One-year Follow-up, Single Center Study
by: İsmail Tunçekin, et al.
Published: (2023-12-01)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
by: Yang Sun, et al.
Published: (2022-05-01)

Does the VDR gene polymorphism influence the efficacy of denosumab therapy in postmenopausal osteoporosis?
by: Anna Wawrzyniak, et al.
Published: (2023-01-01)

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
by: Shahin Nargesi, et al.
Published: (2022-07-01)

The efficacy of denosumab in Korean male patients with osteoporosis
by: Chaiho Jeong, et al.
Published: (2022-09-01)

Denosumab for the treatment of osteoporosis
by: Michael R. McClung
Published: (2017-03-01)

Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab
by: Zhanna E. Belaya, et al.
Published: (2018-04-01)

Effectiveness of Denosumab in Postmenopausal Osteoporosis Treatment: A 1-yr Follow-up Single-center Study
by: Nihal Tezel, et al.
Published: (2021-12-01)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
by: Yilin Zhu, et al.
Published: (2020-05-01)

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
by: Arina Miyoshi, et al.
Published: (2021-07-01)

Long-term consequences of osteoporosis therapy with denosumab
by: Francisco Bandeira, et al.
Published: (2022-12-01)

Comparative evaluation of denosumab efficacy of in patients with rheumatoid arthritis and postmenopausal osteoporosis: results of 1-year study in clinical practice
by: O. V. Dobrovolskaya, et al.
Published: (2019-05-01)

Effect of Denosumab on Bone Density in Postmenopausal Osteoporosis: A Comparison with and without Calcium Supplementation in Patients on Standard Diets in Korea
by: Chaiho Jeong, et al.
Published: (2023-11-01)

Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy
by: Ning Zhang, et al.
Published: (2020-05-01)

Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
by: Suzuki T, et al.
Published: (2018-12-01)

Antiresorptive activity of denosumab in the treatment of osteoporosis in patients with rheumatoid arthritis
by: Nadezhda Y. Banshchikova, et al.
Published: (2018-12-01)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
by: Mingwei Hu, et al.
Published: (2023-07-01)

Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study
by: Chaiho Jeong, et al.
Published: (2023-04-01)

A randomized placebo-controlled trial of the efficacy of denosumab in Indian postmenopausal women with osteoporosis
by: Shailesh Pitale, et al.
Published: (2015-01-01)

Effects of 3-year denosumab treatment on hip structure in Japanese postmenopausal women and men with osteoporosis
by: Teruki Sone, et al.
Published: (2017-12-01)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
by: Uehara M, et al.
Published: (2018-05-01)

Interstitial Lung Disease in a Patient Treated with Denosumab
by: Ana Campo Ruiz, et al.
Published: (2019-07-01)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
by: Yasuaki Hirooka, et al.
Published: (2021-09-01)

Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial
by: Ahmadreza Jamshidi, et al.
Published: (2022-06-01)

Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis
by: Filippo Migliorini, et al.
Published: (2021-08-01)

Long-Term Treatment of Postmenopausal Osteoporosis
by: Jacques P. Brown
Published: (2021-06-01)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
by: Chuanjian Yuan, et al.
Published: (2023-06-01)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
by: Jiaqi Wu, et al.
Published: (2018-08-01)

Efficacy of denosumab therapy for neurofibromatosis type I with osteoporosis and history of fractures: a case report
by: Uehara M, et al.
Published: (2018-07-01)

Denosumab treatment and infection risks in patients with osteoporosis: propensity score matching analysis of a national-wide population-based cohort study
by: Shih-Ting Huang, et al.
Published: (2023-05-01)

Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis
by: Yukio Nakamura, et al.
Published: (2017-04-01)

THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE
by: N. V. Toroptsova, et al.
Published: (2017-07-01)

Long-term follow up after denosumab treatment for osteoporosis – rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report
by: Yves Maugars, et al.
Published: (2020-08-01)